Page 674 - Hematology_ Basic Principles and Practice ( PDFDrive )

570.e6 Part V Red Blood Cells

252. Voskaridou E, Terpos E: New insights into the pathophysiology and 279. Chatterjee R, Katz M: Reversible hypogonadotrophic hypogonadism
management of osteoporosis in patients with beta thalassaemia. Br J in sexually infantile male thalassaemic patients with transfusional iron
Haematol 127(2):127–139, 2004. overload. Clin Endocrinol (Oxf) 53:33, 2000.
253. Terpos E, Voskaridou E: Treatment options for thalassemia patients 280. Merkel PA, Simonson DC, Amiel SA, et al: Insulin resistance and
with osteoporosis. Ann N Y Acad Sci 1202:237–243, 2010. hyperinsulinemia in patients with thalassemia major treated by hyper-
254. Wong P, Fuller PJ, Gillespie MT, et al: Thalassemia bone disease: a transfusion. N Engl J Med 318:809, 1988.
19-year longitudinal analysis. J Bone Miner Res 29(11):2468–2473, 281. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, et al: High
2014. prevalence of diabetes mellitus among adult beta-thalassaemic patients
255. Giardina P, Schneider R, Lesser M, et al: Abnormal bone metabolism with chronic hepatitis C. Eur J Gastroenterol Hepatol 11:1033, 1999.
in thalassemia. In Ando S, Brancati C, editors: Endocrine disorders in 282. Chern JP, Lin KH, Lu MY, et al: Abnormal glucose tolerance in
thalassemia, Berlin, Heidelberg, 1995, Springer Verlag, p 39. transfusion-dependent beta-thalassemic patients. Diabetes Care 24:850,
256. Jensen CE, Tuck SM, Agnew JE, et al: High prevalence of low bone 2001.
mass in thalassaemia major. Br J Haematol 103:911, 1998. 283. Pappas S, Donohue SM, Denver AE, et al: Glucose intolerance in
257. Vogiatzi MG, Autio KA, Schneider R, et al: Low bone mass in prepu- thalassemia major is related to insulin resistance and hepatic dysfunc-
bertal children with thalassemia major: insights into the pathogenesis tion. Metabolism 45:652, 1996.
of low bone mass in thalassemia. J Pediatr Endocrinol Metab 17:1415, 284. Ladis V, Theodorides C, Palamidou F, et al: Glucose disturbances and
2004. regulation with glibenclamide in thalassemia. J Pediatr Endocrinol
258. Vogiatzi MG, Autio KA, Mait JE, et al: Low bone mineral density in Metab 11:871, 1998.
adolescents with beta-thalassemia. Ann N Y Acad Sci 1054:462, 2005. 285. Gertner JM, Broadus AE, Anast CS, et al: Impaired parathyroid response
259. Vogiatzi MG, Macklin EA, Fung EB, et al: Prevalence of fractures to induced hypocalcemia in thalassemia major. J Pediatr 95:210, 1979.
among the Thalassemia syndromes in North America. Bone 38:571, 286. Masala A, Meloni T, Gallisai D, et al: Endocrine functioning in mul-
2006. titransfused prepubertal patients with homozygous beta-thalassemia. J
260. Trachtenberg FL, Mednick L, Kwiatkowski JL, et al: Beliefs about che- Clin Endocrinol Metab 58:667, 1984.
lation among thalassemia patients. Health Qual Life Outcomes 10:148, 287. de Luca F, Melluso R, Sobbrio G, et al: Thyroid function in thalassae-
2012. mia major. Arch Dis Child 55:389, 1980.
261. Wong P, Fuller PJ, Gillespie MT, et al: Thalassemia bone disease: a 288. Zervas A, Katopodi A, Protonotariou A, et al: Assessment of thyroid
19-year longitudinal analysis. J Bone Miner Res 29(11):2468–2473, function in two hundred patients with beta-thalassemia major. Thyroid
2014. 12:151, 2002.
262. Fung EB, Kwiatkowski JL, Huang JN, et al: Zinc supplementation 289. Chern JP, Lin KH: Hypoparathyroidism in transfusion-dependent
improves bone density in patients with thalassemia: a double-blind, patients with beta-thalassemia. J Pediatr Hematol Oncol 24:291, 2002.
randomized, placebo-controlled trial. Am J Clin Nutr 98(4):960–971, 290. Angelopoulos NG, Goula A, Rombopoulos G, et al: Hypoparathyroid-
2013. ism in transfusion-dependent patients with beta-thalassemia. J Bone
263. Lawson JP, Ablow RC, Pearson HA: The ribs in thalassemia. I. The Miner Metab 24:138, 2006.
relationship to therapy. Radiology 140:663, 1981. 291. Ellis JT, Schulman I, Smith CH: Generalized siderosis with fibrosis of
264. Caffey J: Cooley’s anemia: a review of the roentgenographic findings in liver and pancreas in Cooley’s (Mediterranean) anemia; with observa-
the skeleton: Hickey lecture, 1957. Am J Roentgenol Radium Ther Nucl tions on the pathogenesis of the siderosis and fibrosis. Am J Pathol
Med 78:381, 1957. 30:287, 1954.
265. Asbell MB: Orthodontic aspects of Cooley’s anemia. Ann N Y Acad Sci 292. Fink H: Transfusion hemochromatosis in Cooley’s anemia. Ann N Y
119:662, 1964. Acad Sci 119:680, 1964.
266. Currarino G, Erlandson ME: Premature fusion of epiphyses in Cooley’s 293. De Virgiliis S, Cornacchia G, Sanna G, et al: Chronic liver disease in
anemia. Radiology 83:656, 1964. transfusion-dependent thalassemia: liver iron quantitation and distribu-
267. Lawson JP, Ablow RC, Pearson HA: Premature fusion of the proximal tion. Acta Haematol 65:32, 1981.
humeral epiphyses in thalassemia. AJR Am J Roentgenol 140:239, 1983. 294. Mak IT, Weglicki WB: Characterization of iron-mediated peroxidative
268. Lawson JP, Ablow RC, Pearson HA: The ribs in thalassemia. II. The injury in isolated hepatic lysosomes. J Clin Invest 75:58, 1985.
pathogenesis of the changes. Radiology 140:673, 1981. 295. Aldouri MA, Wonke B, Hoffbrand AV, et al: Iron state and hepatic
269. Spinal cord compression in thalassemia [editorial]. Lancet 1:664, disease in patients with thalassaemia major, treated with long term
1982. subcutaneous desferrioxamine. J Clin Pathol 40:1353, 1987.
270. Laor E, Garfunkel A, Koyoumdjisky-Kaye E: Skeletal and dental 296. Di Marco V, Lo Iacono O, Almasio P, et al: Long-term efficacy of
retardation in beta-thalassemia major. Hum Biol 54:85, 1982. alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood
271. Johnston FE, Krogman WM: Patterns of growth in children with 90:2207, 1997.
thalassemia major. Ann N Y Acad Sci 119:667, 1964. 297. Telfer PT, Garson JA, Whitby K, et al: Combination therapy with
272. Aydinok Y, Darcan S, Polat A, et al: Endocrine complications in interferon alpha and ribavirin for chronic hepatitis C virus infection in
patients with beta-thalassemia major. J Trop Pediatr 48:50, 2002. thalassaemic patients. Br J Haematol 98:850, 1997.
273. Borgna-Pignatti C, De Stefano P, Zonta L, et al: Growth and sexual 298. Sievert W, Pianko S, Warner S, et al: Hepatic iron overload does not
maturation in thalassemia major. J Pediatr 106:150, 1985. prevent a sustained virological response to interferon-alpha therapy: a
274. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al: Effect of age at the long term follow-up study in hepatitis C-infected patients with beta
start of iron chelation therapy on gonadal function in beta-thalassemia thalassemia major. Am J Gastroenterol 97:982, 2002.
major. N Engl J Med 323:713, 1990. 299. Li CK, Chan PK, Ling SC, et al: Interferon and ribavirin as frontline
275. Scacchi M, Danesi L, De Martin M, et al: Treatment with biosynthetic treatment for chronic hepatitis C infection in thalassaemia major. Br J
growth hormone of short thalassaemic patients with impaired growth Haematol 117:755, 2002.
hormone secretion. Clin Endocrinol (Oxf) 35:335, 1991. 300. Harmatz P, Jonas MM, Kwiatkowski JL, et al: Safety and efficacy
276. Theodoridis C, Ladis V, Papatheodorou A, et al: Growth and manage- of pegylated interferon alpha-2a and ribavirin for the treatment of
ment of short stature in thalassaemia major. J Pediatr Endocrinol Metab hepatitis C in patients with thalassemia. Haematologica 93:1247, 2008.
11:835, 1998. 301. Harmatz P, Olivieri N, Kwiatkowski J, et al: Safety and efficacy of
277. Katzos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa peginterferon Alfa-2a and Ribavirin for hepatitis C in thalassemia.
M, et al: Growth hormone treatment in short children with beta- Blood 108:558, 2006.
thalassemia major. J Pediatr Endocrinol Metab 13:163, 2000. 302. Dewey KW, Grossman H, Canale VC: Cholelithiasis in thalassemia
278. Low LC, Kwan EY, Lim YJ, et al: Growth hormone treatment of short major. Radiology 96:385, 1970.
Chinese children with beta-thalassaemia major without GH deficiency. 303. Kremastinos DT, Tsetsos GA, Tsiapras DP, et al: Heart failure in beta
Clin Endocrinol (Oxf) 42:359, 1995. thalassemia: a 5-year follow-up study. Am J Med 111:349, 2001.